Examining how insulin in the brain affects the immune system during exercise
The Importance of Insulin Action in the Brain for the Immune System During Physical Activity
This study is testing how insulin in the brain affects the immune system during exercise to see if it helps improve physical performance.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 30 Years |
| Sex | All |
| Sponsor | University of Ulm Academic / other |
| Locations | 1 site (Ulm) |
| Trial ID | NCT06552130 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the role of insulin action in the brain on the immune system during physical activity. Participants will undergo bicycle spiroergometer tests on two separate days, receiving either an intranasal insulin spray or a placebo spray in a randomized, blinded manner. The study aims to clarify how brain insulin influences immune responses and physical performance through the autonomic nervous system. Measurements will include immune cell activity, cytokine levels, and gene expression in leukocytes.
Who should consider this trial
Good fit: Ideal candidates are individuals with a BMI less than 24 kg/m2 and no known primary diseases.
Not a fit: Patients with alcohol or drug abuse issues, smoking habits, or any clinical conditions that may jeopardize their safety will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of how insulin action in the brain influences immune function during exercise, potentially leading to improved health outcomes.
How similar studies have performed: While the specific approach of this study may be novel, previous research has indicated that insulin action in the brain can influence various physiological processes, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI \< 24 kg/m2 * no known primary diseases * hormonal contraception with a single-phase preparation Exclusion Criteria: * Alcohol or drug abuse * Smoking * At screening: Hb \< 12 g/dl for women and Hb \< 14 g/dl for men * Any (clinical) condition that would endanger participant's safety or question scientific success according to a physician's opinion.
Where this trial is running
Ulm
- Universityhospital Ulm — Ulm, Germany (Recruiting)
Study contacts
- Principal investigator: Martin Heni, MD — University of Ulm
- Study coordinator: Martin Heni, MD
- Email: martin.heni@uniklinik-ulm.de
- Phone: +4973150044505
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.